Back to Newsroom

Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial Results for the Second Fiscal Quarter and First Half Ended September 30, 2016

HAMILTON, Bermuda, Nov. 7, 2016 /PRNewswire/ — Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced corporate updates and reported financial results for the second fiscal quarter and first half ended September 30, 2016.

Click here to read the full release